C
7.67
-3.51 (-31.38%)
| Penutupan Terdahulu | 11.17 |
| Buka | 8.74 |
| Jumlah Dagangan | 16,683,307 |
| Purata Dagangan (3B) | 2,781,311 |
| Modal Pasaran | 603,918,080 |
| Harga / Pendapatan (P/E TTM) | 3.47 |
| Harga / Pendapatan (P/E Ke hadapan) | 4.03 |
| Harga / Jualan (P/S) | 3.76 |
| Harga / Buku (P/B) | 2.35 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| Margin Keuntungan | 20.81% |
| Margin Operasi (TTM) | 51.49% |
| EPS Cair (TTM) | 0.250 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.41% |
| Nisbah Semasa (MRQ) | 4.21 |
| Aliran Tunai Operasi (OCF TTM) | -13.57 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -21.07 M |
| Pulangan Atas Aset (ROA TTM) | 8.31% |
| Pulangan Atas Ekuiti (ROE TTM) | 19.87% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | CorMedix Inc. | Menurun | Menaik |
AISkor Stockmoo
0.3
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -3.5 |
| Purata | 0.25 |
|
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.08% |
| % Dimiliki oleh Institusi | 34.20% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Oberweis Asset Management Inc/ | 30 Sep 2025 | 785,700 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 22.00 (RBC Capital, 187.02%) | Beli |
| Median | 16.50 (115.26%) | |
| Rendah | 14.00 (D. Boral Capital, 82.65%) | Beli |
| Purata | 17.25 (125.05%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 9.55 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 08 Jan 2026 | 14.00 (82.65%) | Beli | 7.67 |
| 18 Dec 2025 | 14.00 (82.65%) | Beli | 11.92 | |
| Needham | 08 Jan 2026 | 15.00 (95.69%) | Beli | 7.67 |
| 12 Nov 2025 | 16.00 (108.74%) | Beli | 11.42 | |
| HC Wainwright & Co. | 13 Nov 2025 | 18.00 (134.83%) | Beli | 11.21 |
| RBC Capital | 21 Oct 2025 | 22.00 (187.02%) | Beli | 11.65 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Dec 2025 | Pengumuman | CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath |
| 12 Nov 2025 | Pengumuman | Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update |
| 12 Nov 2025 | Pengumuman | CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance |
| 31 Oct 2025 | Pengumuman | CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025 |
| 23 Oct 2025 | Pengumuman | CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath |
| 21 Oct 2025 | Pengumuman | Talphera Announces the Appointment of Joe Todisco to Board of Directors |
| 20 Oct 2025 | Pengumuman | CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |